# Ipamorelin FAQ: Straight Answers from the Research > Ipamorelin FAQ: belly fat, 2024 research, IGF-1, half-life, FDA status, water retention, and the CJC-1295 questions — answered plainly and cited to the studies. The things people actually ask, with the study behind each answer. ## Does ipamorelin reduce belly fat? There is no human trial showing ipamorelin reduces belly fat. The closest evidence is a 2024 ferret study where ipamorelin (1-3 mg/kg) cut chemotherapy-driven weight *loss* by about 24% — that is protecting weight, not burning fat [5]. Community reports of a gradually leaner look are anecdotal and heavily confounded by diet and training. ## Is there new research on ipamorelin in 2024? Yes. The headline 2024 study is the ferret cachexia paper: intraperitoneal ipamorelin inhibited cisplatin-induced body-weight loss by roughly 24% but had no anti-emetic effect [5]. A 2024 tilapia study also showed ipamorelin acetate activated the reproductive hormone axis [13], and a 2024 ghrelin-system paper linked the receptor family to protection of aging muscle [7]. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively triggers growth hormone release by acting on the ghrelin receptor. In its founding study it released GH potently in rats and pigs without raising cortisol or prolactin even at very high doses [1]. It is a research peptide, not an approved drug. ## What does ipamorelin do for you? In research terms, ipamorelin makes the pituitary release a clean pulse of growth hormone without dragging up stress hormones [1]. What that translates to in people is largely unproven — the human record is one small pharmacokinetic study [2] and one failed bowel-surgery trial [3]. Reported sleep and recovery effects are anecdotal, not clinical findings. ## What is ipamorelin peptide? The ipamorelin peptide is a pentapeptide — five amino acids — built to resist enzymatic breakdown and to hit the ghrelin/GH-secretagogue receptor selectively. It mimics the action of natural ghrelin at that receptor, prompting a discrete GH pulse [1]. It is wholly synthetic and is not a hormone your body makes. ## What are the risks of ipamorelin? The biggest risk is the unknown: no Phase 3 trial and no long-term human safety data exist [3]. Class-level concerns include a cardiac signal seen with a related GH-secretagogue in rats [6], theoretical IGF-1-and-cancer worries from GH-axis stimulation [4], and unpredictable blood sugar in people with diabetes [18]. Gray-market purity is also unverified. ## What are the downsides of ipamorelin? On the evidence side, the main downside is that ipamorelin's one efficacy trial failed [3] and human data is scarce [2]. On the experience side, community reports include facial flushing, tingling, mild water retention, more hunger, and injection-site irritation — all anecdotal, not clinical findings. The full reported list is on the [Ipamorelin effects](/effects) page. ## Why is ipamorelin being discontinued? Ipamorelin was never a marketed drug, so it was not 'discontinued' in the usual sense — its only clinical program (postoperative ileus) ended after the Phase 2 trial missed its endpoint [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access. ## What does CJC-1295 and ipamorelin do? Together they aim to raise growth hormone through two different receptors: CJC-1295 (a GHRH analog) provides a steady signal that raised GH and IGF-1 multi-fold in healthy adults [3], while ipamorelin adds a sharp, selective GH pulse [1]. The combination itself has never been formally trialed, so its real-world effects are unproven. ## Does ipamorelin increase IGF-1? Not reliably in short studies. In the 15-day rat bone-growth study, ipamorelin raised bone growth with **no** measurable change in total IGF-1 [4]. Sustained GH-axis stimulation is mechanistically linked to IGF-1 over time, but ipamorelin does not consistently elevate IGF-1 in brief rodent protocols, which complicates the simple GH-to-IGF-1 story. ## How does CJC-1295 ipamorelin work? CJC-1295 binds the GHRH receptor for a long-lasting background push on GH and IGF-1 [3], while ipamorelin binds the ghrelin/GHS-R1a receptor for a clean, selective GH pulse without raising cortisol [1]. The idea is that combining a steady GHRH signal with a pulsatile GHRP raises GH more naturally — though the pairing has never been tested as a unit. ## How much CJC-1295 ipamorelin should I take? There is no research-validated dose for the cjc-1295 ipamorelin combination — it has never been tested in a controlled human trial. The single agents have separate pharmacology [2][3], but that does not establish a safe combined dose. Online subcutaneous regimens are anecdotal, not recommended. A qualified clinician, not a forum, is the right source here. ## Does CJC-1295 ipamorelin work? The individual mechanisms work — CJC-1295 raised GH and IGF-1 in healthy adults [3], and ipamorelin reliably fires a GH pulse [1][2]. But for the outcomes people want (fat loss, muscle, anti-aging), no controlled human trial of the combination demonstrates any of them, and ipamorelin's own human evidence is thin and partly negative [3]. ## How to reconstitute CJC-1295 ipamorelin 5mg? As a handling matter, ipamorelin ships as a freeze-dried powder reconstituted with bacteriostatic water in the research-supply literature, then kept refrigerated because peptides degrade with heat and freeze-thaw [2]. This is a general handling observation, not a clinical preparation or dosing instruction, and the specific volumes quoted online are unverified and outside any approved use. ## How long does ipamorelin stay in your system? Ipamorelin's terminal half-life in healthy human volunteers is about 2 hours, with the GH pulse it triggers peaking near 40 minutes after dosing [2]. As a rule of thumb, a compound is largely cleared after several half-lives, so the parent peptide does not persist long — though anti-doping labs can still detect GHRP metabolites in urine. ## Does ipamorelin make you hungry? It can, by mechanism. Ipamorelin acts on the ghrelin receptor — ghrelin is the body's 'hunger hormone' — and ghrelin-receptor agonists activate brain appetite centers and induce feeding as a class [17]. Community reports describe an appetite bump after dosing, usually called milder than GHRP-6 [16]. A 2026 review also notes ipamorelin's promotion for body composition despite limited controlled data [12]. ## Will I gain weight on ipamorelin? Possibly, and not always as muscle. Ipamorelin raised body fat and leptin in both GH-deficient and GH-intact mice after two weeks, showing part of the weight effect is GH-independent [16]. Its appetite-stimulating action can also drive intake [17]. The one human efficacy trial was for bowel surgery, not weight, and it failed [3] — so any weight claim is unproven in people. ## Does ipamorelin increase appetite? Yes, at the mechanism level. As a ghrelin-receptor agonist, ipamorelin sits in a class that activates hypothalamic appetite circuitry and induces feeding [17], and a 2026 review situates it among GH-secretagogues promoted for metabolism despite thin controlled data [12]. Community accounts call the appetite bump real but milder than older GHRPs like GHRP-6 [16]. ## What does ipamorelin peptide do? The ipamorelin peptide selectively activates the ghrelin/GH-secretagogue receptor on the pituitary to release a discrete pulse of growth hormone, without meaningfully raising ACTH, cortisol, or prolactin [1]. Downstream, GH can feed the IGF-1 axis, though that is not consistent in short rodent studies [4]. In humans, its proven effects beyond pharmacokinetics are limited [2][3]. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the GH pulse ipamorelin triggers peaks around 40 minutes after an IV dose and the peptide clears with a ~2-hour half-life [2]. But that is the hormone response, not a clinical 'result.' Any longer-term effects people describe are anecdotal and accumulate over weeks, with no controlled human timeline to confirm them. ## Does ipamorelin cause water retention? Community reports describe mild, transient water retention or puffiness early on, generally called milder than with older GH-releasing peptides — but this is anecdotal, not a clinical finding. Mechanistically, GH excess is associated with sodium and water retention, which is part of why fluid-overload conditions appear among the cited safety cautions [6]. No controlled human study has quantified it for ipamorelin. ## Where to inject CJC-1295 ipamorelin? This site does not provide injection instructions, because that crosses from research digest into personal-use guidance, and ipamorelin has no approved human use. The literature notes subcutaneous injection is the dominant community route and the one used in rodent body-composition studies [4], but the safety of human self-injection has never been characterized [2]. Injection technique is a question for a qualified clinician, not a website. --- New studies first, plain English always — an independent ipamorelin reading list, never a clinic, a prescription, or a store.